Sertindole: Pharmacological and clinical profile and role in the treatment of schizophrenia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 5, 2008, Pages 629-638

  Spina, Edoardo ^a   Zoccali, Rocco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antipsychotics; Cardiovascular risk; Extrapyramidal symptoms; QTc interval prolongation; Schizophrenia; Sertindole

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPRAZOLAM; AMIODARONE; AMISULPRIDE; ASTEMIZOLE; CLOZAPINE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; DROPERIDOL; ERYTHROMYCIN; GLYCOPROTEIN P; HALOPERIDOL; KETOCONAZOLE; OLANZAPINE; OROSOMUCOID; PLACEBO; POTASSIUM CHANNEL HERG; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTINDOLE; SERUM ALBUMIN; TERFENADINE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE;

AKATHISIA; AREA UNDER THE CURVE; BINDING AFFINITY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONVULSION; DEALKYLATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EJACULATION; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HEART ARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HYPOTENSION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NEGATIVE SYNDROME; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RECEPTOR OCCUPANCY; REVIEW; RHINITIS; SCHIZOPHRENIA; SEDATION; SHORT QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOMNOLENCE; SUDDEN DEATH; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS, NON-NARCOTIC; ANESTHESIA; ANIMALS; DEXMEDETOMIDINE; DRUG INTERACTIONS; HUMANS; HYPNOTICS AND SEDATIVES;

EID: 45949095610     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.5.629     Document Type: Review

References (62)

1. Stahl S. Essential psychopharmacology of antipsychotics and mood stabilizers. Cambridge: CUP; 2002
2. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21:911-36
3. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Amipsychotic Trial of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 2005;353:1209-23
4. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Cost Utility of the Latest Antipsychoric Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
5. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs 2006;20:233-55
6. Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Exp Opin Drug Saf 2006;7:1825-34
7. Moore N. Higher cardiovascular mortality with sertindole in ADROIT. a signal not confirmed. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S3-9
8. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 199 1;22:239-42
9. 2 and alpha one receptors. 3 Neural Trasm 1992;89:61-9
10. Arnt J, Skarsfeldt T Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101
11. Horacek J, Bubenikowa-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20:389-409
12. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther 2000;295:226-32
13. 2C receptors after chronic treatment. Psychopharmacology 2001;157:180-7
14. Nyberg S, Olsson H, Nilsson U, et al. Low striatal and extrastriatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 2002;162:37-41
15. 18F-setoperone in the normal human cortex. J Nud Med 1999;40:25-32
16. Didriksen M. Effects of antipsychotics on cognitive behaviour in rats using the delayed non-match position paradigm. Eurj Pharmacol 1995;28 1:241-50
17. Skarsfeldt T Differential effect of antipsychotics on place navigation of rats in the Morris Water maze. A comparative study between novel and reference antipsychotics. Psychopharmacology 1996;124:126-33
18. Didriksen M, Kreilgaard M, Arnt J. Sertindole, in contrast to dozapine and olanzapine, does not disrupt water maze performance after acute or chronic treatment. Eur J Pharmacol 2006;542:108-15
19. Didriksen M, Skarfeldt T, Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris'water maze by sertindole and other antipsychotics. Psychopharmacology 2007;193:225-33
20. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J. Reversal of subcbronic PCP-induced deficits in attentionall set shifting in rats by sertindole and a 5-HT6; receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2007 [Epub ahead of print]
21. Titier K, Girodet PO, Verdoux H, et al. Atypical antipsychotics: from potassium channels to torsde de pointes and sudden death. Drug Saf 2005;28:35-51
22. RampeD,MurawskyMK,Grauj,etal. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 1998;286:788-93
23. Kongsamut S, Kang J, Chen XL, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41
24. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71
25. Drici MD, Wang WX, Liu XK, et al. Prolongation of QT interval in isolated feline hearths by antipsychotic drugs. J Clin Psychopharmacol 1998; 18:477-81
26. Eckardt L, Breithardt G, Haverkamp W Electrophysiologic characterisation of the antipsychotic drug sertindole in a rabbit hearth model of Torsade de Pointes; low corsadogenic potential
27. Thomsen MB, Volders PGA, Stengl M, et al. Electrophysiological safety of sertindole in dogs with normal and remodeled hearts. J Pharmacol Exp Ther 2003;307:776-84
28. Haverkamp W, Eckardt L, Matz J. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002;6(Suppl 1):S11-20
29. Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatment: focus on sertindole. Int J Neuropsychopharmacol 2005;8:615-29
30. Wong SL, Linen P, Mack RJ, Granneman GR. Effects of food, antacid, and dosage form on the phamacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos 1997;18:533-41
31. Wong SL, Cao G, Mack RJ, Granneman GR. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997;62:157-64
32. Wong SL, Menacherry S, Mulford D, et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997;52:223-7
33. Wong SL, Granneman R. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. J Pharm Sci 1998;87:1629-31
34. H. Lundbeck A/S. Serdolect (sertindole) monograph. Copenhagen: H Lundbeck A/S; 2005
35. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005;33:165-74
36. Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology 2006;187:415-23
37. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-88
38. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
39. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychtics. J Clin Psychiatry 1996;57(Suppl 11):12-25
40. Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 1998;135:236-41
41. Wong SL, Cao G, Mack R, Granneman GR. Lack of CYP3A inhibition effects of sertindole on terfenadine in healthy volunteers. Int J Clin Pharmacol Ther 1998;36:146-51
42. Wong SL, Cao G, Mack RJ, Granneman GR. The effect of erythromycin on the CYP3A component of sertindole clearance in healthy volunteers. J Clin Pharmacol 1997;37:1056-61
43. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996;124:168-75
44. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91
45. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a Phase III trial. Int J Psychiatry Clin Pract 2000;4:55-62
46. Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998;34:61-9
47. Azorin JM, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006;21:49-56
48. Tamminga CA, Mack RJ, Granneman GR, et al. Sertindole in the treatment of psychosis in the schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997;12(Suppl 1):S29-35
49. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004;18(Suppl 2):19-30
50. Gallhofer B, Jaanson P, Mittoux A, et al. Course of recovery of cognitive impairment in patients with schizophrenia: a randomized double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007;40:275-86
51. Hale A, Azorin JM, Kasper S, et al. Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a Phase III trial. Int J Psychiatry Clin Pract 2000;4:47-54
52. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev 2005;3:CD001715
53. Perquin LN. Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects. Int Clin Psychopharmacol 2005;20:335-8
54. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
55. Kasper S, Tuomi M. The clinical safety and tolerability profile of sertindole [abstract no. S422]. Int J Neuropsychopharmacol 2004;7(Suppl 1):S422
56. Mack R, Driscoll R, Silber C. The long term cardiovascular safety of sertindole. Eur Neuropsychopharmacol 1997;7(Suppl 2):S207
57. Agelink MW, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13
58. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and in the presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9
59. Wilton L, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6
60. Branford D, Thompson B, Mouldon C. Mortality in three comparative cohorts of patients who received sertindole, risperidone and olanzapine: a hospital-based, retrospective study [abstract no. 247]. Pharmacoepidemiol Drug Saf 2002;11(Suppl 1):S116
61. Peuskens J, Moore N, Azorin JM, et al. The European sertindole safety and exposure survey: a follow-up study of 8600 patients. Pharmacoepidemiol Drug Saf 2007;16:804-11
62. Moore N, Hall G, Sturkenboom M, et al. Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003;12:271-81